Key Points
- Glenbrook Capital Management bought 146,249 shares of Senestech on March 13 at an average price of $1.95 (total ~$285,185), raising its direct stake by 20.32% to 865,850 shares valued at ~$1.69 million.
- Glenbrook has been actively accumulating SNES across February–March, purchasing roughly 296,850 shares in the reported transactions for a combined outlay of about $602,488, indicating sustained insider accumulation.
- Senestech is a small-cap biotech (market cap ~$9.38 million) with negative earnings and profitability (latest EPS -$0.29 and a negative net margin of ~287%), and the stock carries a consensus "Hold" rating from analysts.
Senestech, Inc. (NASDAQ:SNES - Get Free Report) major shareholder Glenbrook Capital Management acquired 146,249 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was acquired at an average cost of $1.95 per share, for a total transaction of $285,185.55. Following the completion of the transaction, the insider directly owned 865,850 shares in the company, valued at $1,688,407.50. This represents a 20.32% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Glenbrook Capital Management also recently made the following trade(s):
- On Tuesday, March 17th, Glenbrook Capital Management bought 19,725 shares of Senestech stock. The shares were acquired at an average price of $1.79 per share, for a total transaction of $35,307.75.
- On Monday, March 16th, Glenbrook Capital Management bought 5,060 shares of Senestech stock. The stock was acquired at an average cost of $1.86 per share, with a total value of $9,411.60.
- On Thursday, February 19th, Glenbrook Capital Management purchased 34,613 shares of Senestech stock. The stock was acquired at an average price of $2.40 per share, with a total value of $83,071.20.
- On Wednesday, February 18th, Glenbrook Capital Management purchased 10,481 shares of Senestech stock. The shares were acquired at an average cost of $2.29 per share, for a total transaction of $24,001.49.
- On Tuesday, February 17th, Glenbrook Capital Management acquired 40,807 shares of Senestech stock. The shares were acquired at an average cost of $2.29 per share, for a total transaction of $93,448.03.
- On Friday, February 13th, Glenbrook Capital Management acquired 15,390 shares of Senestech stock. The shares were acquired at an average cost of $1.89 per share, for a total transaction of $29,087.10.
- On Thursday, February 12th, Glenbrook Capital Management acquired 7,956 shares of Senestech stock. The stock was acquired at an average price of $1.72 per share, with a total value of $13,684.32.
- On Wednesday, February 11th, Glenbrook Capital Management bought 8,000 shares of Senestech stock. The stock was acquired at an average cost of $1.73 per share, with a total value of $13,840.00.
- On Thursday, February 5th, Glenbrook Capital Management bought 2,884 shares of Senestech stock. The shares were bought at an average price of $1.77 per share, for a total transaction of $5,104.68.
- On Wednesday, February 4th, Glenbrook Capital Management bought 5,685 shares of Senestech stock. The shares were bought at an average price of $1.82 per share, for a total transaction of $10,346.70.
Senestech Stock Performance
Shares of NASDAQ SNES opened at $1.77 on Wednesday. The firm's 50-day moving average price is $2.06 and its 200-day moving average price is $2.97. Senestech, Inc. has a 52-week low of $1.30 and a 52-week high of $6.24. The company has a market cap of $9.38 million, a PE ratio of -0.64 and a beta of 0.15. The company has a quick ratio of 14.73, a current ratio of 12.61 and a debt-to-equity ratio of 0.02.
Senestech (NASDAQ:SNES - Get Free Report) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.01. The firm had revenue of $0.42 million during the quarter, compared to analysts' expectations of $0.78 million. Senestech had a negative net margin of 287.39% and a negative return on equity of 78.74%. As a group, analysts anticipate that Senestech, Inc. will post -10.22 EPS for the current year.
Institutional Investors Weigh In On Senestech
A number of large investors have recently made changes to their positions in SNES. Sabby Management LLC increased its position in shares of Senestech by 195.4% during the 4th quarter. Sabby Management LLC now owns 210,564 shares of the company's stock valued at $451,000 after purchasing an additional 139,281 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Senestech by 35.2% in the fourth quarter. Renaissance Technologies LLC now owns 142,800 shares of the company's stock worth $306,000 after buying an additional 37,165 shares during the last quarter. DRW Securities LLC grew its position in Senestech by 171.1% during the fourth quarter. DRW Securities LLC now owns 82,107 shares of the company's stock valued at $176,000 after buying an additional 51,818 shares during the period. Corsair Capital Management L.P. bought a new stake in Senestech during the second quarter valued at approximately $255,000. Finally, Jane Street Group LLC purchased a new stake in Senestech during the second quarter valued at approximately $161,000. 5.19% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Senestech in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold".
Get Our Latest Report on Senestech
About Senestech
(
Get Free Report)
SenesTech, Inc (NASDAQ: SNES) is a biotechnology company specializing in non-lethal pest management solutions. The company's core focus is the development and commercialization of fertility-based control methods for commensal rodents, providing an alternative to traditional rodenticides. By targeting the reproductive cycle of rats, SenesTech aims to reduce rodent populations over time without the use of toxic chemicals, offering a more sustainable approach for pest management professionals.
The company's flagship product, ContraPest®, is an EPA-registered liquid bait that disrupts rodent reproduction.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].